Pharmacognosy intro
Rhodiola rosea L., family Crassulaceae, is an arctic-alpine succulent known as Golden Root, Arctic Root, or Roseroot. The root and rhizome are used. Primary bioactives include the phenylethanoid salidroside (rhodioloside), phenylpropanoid rosavins (rosavin, rosarin, rosin), tyrosol, rhodioflavonoside, and gallic acid. Standardization follows the natural 3:1 ratio of rosavins to salidroside (minimum 3% rosavins, 1% salidroside). The SHR-5 extract is the most clinically studied preparation. Over 200 Rhodiola species exist, but only R. rosea contains the rosavins that define its pharmacological profile. Adulteration with R. crenulata (which contains salidroside but lacks rosavins) is common. The primary adaptogenic mechanism operates through HPA axis modulation. Salidroside normalizes elevated corticosterone and cortisol under chronic stress by regulating hypothalamic CRH secretion and inhibiting p-SAPK/JNK phosphorylation (stress-activated protein kinase). This is complemented by upregulation of Hsp72 (heat shock protein 72) for cytoprotection and neuropeptide Y for endogenous stress resilience. Rhodiola inhibits both MAO-A and MAO-B, increasing synaptic availability of serotonin, dopamine, and norepinephrine. Wang et al. (2025, Biomed Chrom) identified an ESR1 (estrogen receptor alpha)/serotonergic pathway interaction for salidroside. Neuroprotective activity involves PI3K/Akt survival pathway activation and Nrf2/ARE antioxidant response, with documented protection against 6-OHDA and MPTP neurotoxicity in Parkinson's models. Olsson et al. (2009, Planta Med) demonstrated in 60 burnout patients that SHR-5 576mg/day for 28 days produced significant cortisol reduction (P<0.01) with improved attention and reduced fatigue. Darbinyan et al. (2007, Phytomedicine) showed both 340mg and 680mg doses significantly improved Hamilton Depression Rating Scale scores versus placebo in mild-to-moderate depression (n=89, 6-week RCT). De Bock et al. (2004, Int J Sport Nutr Exerc Metab) found acute 200mg dosing improved exercise endurance capacity and reduced rate of perceived exertion. The biphasic dose-response (stimulant at low doses, anxiolytic at higher doses) is clinically important but not fully characterized in human dose-response studies. SHR-5 studies are well-designed but relatively small, and not all commercial products match SHR-5 standardization.